Astria to be Acquired in $700M Deal

Boston-based Astria is being acquired by BioCryst Pharmaceuticals in a deal worth about $700 million. Astra is focused on developing therapies for allergic and immunologic diseases. The company’s lead product candidate navenibart is an injectable, long-acting, monoclonal antibody inhibitor of plasma kallikrein for hereditary angioedema (HAE) prophylaxis and could offer significant improvements over existing injectable options.

BioCryst’s established commercialization infrastructure and deep expertise in HAE are expected to maximize the reach of navenibart, expanding access for patients. With the addition of navenibart, BioCryst’s portfolio will include both a leading oral and potentially best-in-class injectable therapy for HAE.

BioCryst Pharmaceuticals is a global biotech with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. (Source: Astria Therapeutics Website, 14 October, 2025)